Accepting New Patients
Accepting New Patients
Peter Chen, MD
4.9
15 Reviews
310-423-8784
Fax: 310-423-2665
4.9
15 Reviews
Peter Chen, MD
Scheduling
In person visits
Fax: 310-423-2665
Advanced Lung Disease
8723 Alden Dr #260
Los Angeles, CA
34.075788 -118.382428From You
4.9
15 Reviews
Accepting New Patients
Peter Chen, MD
Languages
- English,
- Chinese (Mandarin),
Gender
Male
Locations
Advanced Lung Disease
Advanced Lung Disease
310-423-2665 (Fax)
- Self-parking is available in Cedars-Sinai parking lots P1, P2 and P4. 1st hour free, $5 each hour thereafter and $15 daily maximum. Valet parking is the same price as self-parking. Gratuities are not accepted.
Experience
Specialties
Area in which a healthcare provider is highly trained and often board certified.
1
- IM Pulmonary Medicine
Programs
Cedars-Sinai clinical programs this provider is part of:
7
Research Areas
Titles
- Medallion Chair, Molecular Medicine
- Director, Division of Pulmonary and Critical Care Medicine
- Assistant Director, Women's Guild Lung Institute
- Professor, Medicine and Biomedical Sciences
Education & Training
-
University of Washington Medical Center
Fellowship - Completed 2005
-
University of Texas Southwestern Medical Center
Residency - Completed 2002
Achievements
-
2
Board Certifications
-
6
Awards and Honors
Board Certifications
-
IM/Pulmonary Medicine
American Board of Internal Medicine
-
IM/Critical Care
American Board of Internal Medicine
Awards and Honors
- Editorial Board: American Journal of Respiratory Cell and Molecular Biology
- VA Merit Study Section
- Medallion Chair in Molecular Medicine
- NIH Lung Injury, Repair, and Regeneration (LIRR) Study Section
- Chair, Ziskind Clinical Scholars Program, American Thoracic Society (ATS) Foundation
- Jo Rae Wright Award for Outstanding Science, American Thoracic Society
Publications
- Modes ME, Directo MP, Melgar M, Johnson LR, Yang H, Chaudhary P, Bartolini S, Kho N, Noble PW*, Isonaka S*, Chen P*. Clinical characteristics and outcomes among adults hospitalized with laboratory-confirmed SARS-CoV-2 infection during periods of B.1.617.2 (Delta) and B.1.1.529 (Omicron) variant predominance — one hospital, California, July 15–September 23, 2021 and December 21, 2021–January 27, 2022. MMWR Morb Mortal Wkly Rep. 2022 Feb 11;71(6):217-223.
- Yao C, Bora SA, Parimon T, Zaman T, Friedman OA, Palatinus JA, Surapaneni NS, Matusov YP, Cerro Chiang G, Kassar AG, Patel N, Green CER, Aziz AW, Suri H, Suda J, Lopez AA, Martins GA, Stripp BR, Gharib SA*, Goodridge HS*, Chen P*. Cell type-specific immune dysregulation in severely ill COVID-19 patients. Cell Rep. 2021; 34:108590.
- Gottlieb RL, Nirula A, Chen P, Boscia J, Heller B, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Kumar P, Adams CS, Van Naarden J, Custer K, Durante M, Oakley G, Shade Ae, Holzer TR, Ebert PJ, Higgs RE, Kallewaard NL, Sabo J, Patel DR, Klekotka P, Shen L, Skovronsky DM. Effect of neutralizing monoclonal antibody bamlanivimab as monotherapy or in combination with etesevimab on viral load among patients with mild-to-moderate COVID-19: A randomized clinical trial. JAMA. 2021 Feb 16;325(7):632-644. doi: 10.1001/jama.2021.0202. PubMed PMID: 33475701; PubMed Central PMCID: PMC7821080.
- Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, Huhn G, Cardona J, Mocherla B, Stosor V, Shawa I, Adams AC, Van Naarden J, Custer KL, Shen L, Durante M, Oakley G, Schade AE, Sabo J, Patel DR, Klekotka P, Skovronsky DM. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19. N Engl J Med 2021 Jan 21;384(3):229-237.
- Parimon T, Yao C, Habiel DM, Ge L, Bora S, Brauer R, Evans CM, Xie T, Jiang D, Noble PW, Hogaboam CM, Deng N, Burgy O, Antes TJ, Konigshoff M, Stripp BR, Gharib S, Chen P. Syndecan-1 promotes lung fibrosis by regulating epithelial reprogramming through extracellular vesicles. JCI Insight. 2019 4(17):e129359.
- Hornick EE, Dagvadorj J, Zacharias ZR, Miller AM, Langlois RA, Chen P, Legge KL, Bishop GA, Sutterwala FS, Cassel SL. Dendritic cell NLRC4 regulates influenza A virus-specific CD4 T cell responses through FasL expression. J Clin Invest. 2019 Apr 30;130:2888-2897.
- Parimon T, Brauer R, Schlesinger SY, Xie T, Jiang D, Ge L, Huang Y, Birkland TP, Parks WC, Habiel DM, Hogaboam CM, Gharib SA, Deng N, Liu Z, Chen P. Syndecan-1 Controls Lung Tumorigenesis by Regulating miRNAs Packaged in Exosomes. Am J Pathol. 2018 Apr;188(4):1094-1103.
- Ge L, Habiel DM, Hansbro PM, Kim RY, Gharib SA, Edelman JD, Königshoff M, Parimon T, Brauer R, Huang Y, Allen J, Jiang D, Kurkciyan AA, Mizuno T, Stripp BR, Noble PW, Hogaboam CM, Chen P. miR-323a-3p regulates lung fibrosis by targeting multiple pro-fibrotic pathways. JCI Insight. 2016. 1(20):e90301.
- Brauer R, Ge L, Schlesinger SY, Birkland TP, Huang Y, Parimon T, Lee V, McKinney BL, McGuire JK, Parks WC, Chen P. Syndecan-1 Attenuates Lung Injury during Influenza Infection by Potentiating c-Met Signaling to Suppress Epithelial Apoptosis. Syndecan-1 Activates c-Met to Potentiate Lung Injury During Influenza Infection. Am J Resp Crit Care Med. 2016. 194(3):333-44.
- Altemeier WA, Schlesinger SY, Buell CA, Rapraeger AC, Parks WC, Chen P. The Transmembrane and Extracellular Domains of Syndecan-1 Have Distinct Functions in Regulating Lung Epithelial Migration and Adhesion. J Biol Chem. 2012. 287(42): 34927-35.
- Altemeier WA, Schlesinger SY, Buell CA, Parks WC, Chen P. Syndecan-1 Controls Cell Migration by Activating Rap1 to Regulate Focal Adhesion Disassembly. J Cell Sci. 2012. 125:5188-95.
Insurances
Before scheduling your appointment, we strongly recommend you contact your insurance company to verify that the Cedars-Sinai location or provider is included in your network.